NCT06433479Completed
Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 15 Jul 2025
Brief summary (registry, in English)
This is a single-center, parallel-group, randomized, open-label trial evaluating the effect of 3-month treatment with dapagliflozin 10mg once daily on the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation in patients without diabetes, heart failure, or chronic kidney disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 23 May 2024
- Start date
- 15 Jul 2024
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Beijing Anzhen Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT06433479
What you commit to
- Study type: Interventional
- Participants enrolled: 200
- From 15 Jul 2024 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- type 1 diabetes, or previous diabetic ketoacidosis
- planned surgery or other interventional procedure within 3 months
Other illness
- diagnosed with atrial fibrillation secondary to reversible causes (such as hyperthyroidism, acute infection, etc.)
- severe structural heart disease (hypertrophic cardiomyopathy, rheumatic heart disease, dilated cardiomyopathy, etc.)
- severe hypoglycemia or genitourinary infection in the past 12 months
- other arrhythmias mandating anti-arrhythmic drug therapy
- active infection
- other condition unsuitable to participate in this study judged by investigators
Lab values
- currently take sodium-glucose co-transporter 2 inhibitors
- have the following Class I indications for sodium-glucose co-transporter 2 inhibitors: i. type 2 diabetes ii. history of heart failure (HF), including HF with reduced ejection fraction, mildly reduced ejection fraction, and preserved ejection fraction iii. chronic kidney disease with eGFR=20-60 ml/min/1.73m2
- have the following contraindication of sodium-glucose co-transporter 2 inhibitors: i. previous allergic reactions to dapagliflozin ii. end-stage renal failure or dialysis
Other
- diagnosed with persistent atrial fibrillation longer than 5 years or left atrial anterior-posterior diameter ≥ 50mm
- hypovolemia or hypotension
- have intracardiac thrombus
- unable to give informed consent
- women of childbearing potential
- currently enrolled in another clinical study
Who the study is looking for
- age between 18-80 years
- diagnosed with persistent atrial fibrillation based on ECG or Holter
- planned initial catheter ablation for atrial fibrillation
- have the capacity to understand and sign an informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Anzhen Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
- Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.Circulation · 2026 · PMID 41206792
This page is information, not medical advice. Discuss any trial with your doctor.